222 related articles for article (PubMed ID: 32917825)
1. Treating adults with spinal muscular atrophy with nusinersen.
Farrar MA; Kiernan MC
J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1139. PubMed ID: 32917825
[No Abstract] [Full Text] [Related]
2. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
[No Abstract] [Full Text] [Related]
3. Long-term benefits of nusinersen in a child affected by cystic fibrosis and spinal muscular atrophy type 1.
Bruno G; Donnarumma B; Inverardi A; Buonpensiero P; Sepe A; Tosco A; Raia V; Varone A
Pediatr Pulmonol; 2021 Jun; 56(6):1806-1808. PubMed ID: 33684256
[No Abstract] [Full Text] [Related]
4. Nusinersen treatment in a type 3 spinal muscular atrophy patient during early pregnancy.
Schön M; Domingues S; de Carvalho M; Oliveira Santos M
Neurol Sci; 2023 May; 44(5):1803-1804. PubMed ID: 36645532
[No Abstract] [Full Text] [Related]
5. Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy.
Ferrante L; Melendez-Zaidi A; Lindsey W; Lotze T
Muscle Nerve; 2022 Aug; 66(2):E8-E10. PubMed ID: 35616550
[No Abstract] [Full Text] [Related]
6. Stability of serial platelet and urine protein measurements in patients receiving nusinersen for spinal muscular atrophy.
Nagarajan EK; Özütemiz C; Rubin N; Nascene DR
Muscle Nerve; 2022 Jul; 66(1):76-79. PubMed ID: 35466424
[TBL] [Abstract][Full Text] [Related]
7. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
8. Spinal muscular atrophy: state of the art and new therapeutic strategies.
Messina S; Sframeli M; Maggi L; D'Amico A; Bruno C; Comi G; Mercuri E
Neurol Sci; 2022 Dec; 43(Suppl 2):615-624. PubMed ID: 33871750
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
[TBL] [Abstract][Full Text] [Related]
10. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
11. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
[No Abstract] [Full Text] [Related]
12. Nutritional Therapy in Children With Spinal Muscular Atrophy in the Era of Nusinersen.
Yerushalmy-Feler A; Levy D; Sagi L; Fattal-Valevski A; Shiff YE; Brener A; Cohen S
J Pediatr Gastroenterol Nutr; 2021 Jun; 72(6):e154-e160. PubMed ID: 33492038
[TBL] [Abstract][Full Text] [Related]
13. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
[TBL] [Abstract][Full Text] [Related]
14. Resolution of skin necrosis after nusinersen treatment in an infant with spinal muscular atrophy.
Salmin F; Albamonte E; Morettini V; Gagliano N; Mercuri E; Sansone VA
Muscle Nerve; 2019 Jun; 59(6):E42-E44. PubMed ID: 30811610
[No Abstract] [Full Text] [Related]
15. Two Years of Improved Neurological Function With Nusinersen in a 48-Year-Old Patient With Spinal Muscular Atrophy Type 3.
Shah JS; Rubin DI; Dimberg EL; Owens CR; Gicalone AR; De Oliveira G; Oskarsson BE
Neurologist; 2020 Sep; 25(5):141-143. PubMed ID: 32925486
[TBL] [Abstract][Full Text] [Related]
16. Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen.
Sansone VA; Coratti G; Pera MC; Pane M; Messina S; Salmin F; Albamonte E; De Sanctis R; Sframeli M; Di Bella V; Morando S; d'Amico A; Frongia AL; Antonaci L; Pirola A; Pedemonte M; Bertini E; Bruno C; Mercuri E;
Eur J Neurol; 2021 Feb; 28(2):602-608. PubMed ID: 33012052
[TBL] [Abstract][Full Text] [Related]
17. Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients.
Lavie M; Rochman M; Sagi L; Yerushalmy Feler A; Ovadia D; Cahal M; Be'er M; Sadot E; Fattal-Valevski A; Amirav I
Pediatr Pulmonol; 2022 Mar; 57(3):686-694. PubMed ID: 34921596
[TBL] [Abstract][Full Text] [Related]
18. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy.
Osmanovic A; Ranxha G; Kumpe M; Müschen L; Binz C; Wiehler F; Paracka L; Körner S; Kollewe K; Petri S; Schreiber-Katz O
J Neurol; 2020 Aug; 267(8):2398-2407. PubMed ID: 32361837
[TBL] [Abstract][Full Text] [Related]
19. Nusinersen treatment response markers.
Fyfe I
Nat Rev Neurol; 2022 Jul; 18(7):381. PubMed ID: 35676372
[No Abstract] [Full Text] [Related]
20. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
